Radium Dichloride
drugOn this page
Summary
Radium Dichloride (CHEMBL2111187) is an approved small molecule; indicated across 3 conditions including breast neoplasm and sarcoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2111187 |
| Name | Radium Dichloride |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Radium dichloride, RADIUM DICHLORIDE
Parent form; salt/anhydrous children: CHEMBL2107816
Patent coverage: 1,155 distinct patent families (1,888 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,887 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| sarcoma | 1 | MONDO:0005089 | EFO:0000691 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05133440 | PHASE2 | COMPLETED | A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.